GLP-1 drug approvals: A breakdown

Becker's Healthcare January 29, 2025
Paige Twenter

As of Jan. 29, the FDA has approved more than a dozen glucagon-like peptide-1 receptor agonists for diabetes, weight loss, cardiovascular disease and other indications.

The approved indications for brand-name GLP-1s:

Adlyxin (lixisenatide)

• Type 2 diabetes in adults

Bydureon (exenatide)

• Type 2 diabetes in patients ages 10 years and older

Byetta (exenatide)

• Type 2 diabetes in adults

Mounjaro (tirzepatide)

• Type 2 diabetes in adults

Ozempic (semaglutide)

• Type 2 diabetes in adults
• To reduce the risk of major adverse cardiovascular events in diabetic adults with cardiovascular disease
• To reduce the risk of worsening kidney disease in diabetic adults with chronic kidney disease

Rybelsus (semaglutide)

• Type 2 diabetes in...

Today's Sponsors

Today's Sponsor